Otros idiomas Celldex Therapeutics, Inc.

Acciones

CLDX

US15117B2025

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:01 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
40,93 ^USD	+4,02 %		+12,88 %	+3,20 %

17/04	Celldex Therapeutics, Inc. anuncia la finalización de la inscripción en el estudio de fase 2 de barzolvolimab en pacientes con urticaria crónica inducible	CI
28/02	Celldex Therapeutics propone una oferta pública suscrita de 250 millones de dólares en acciones ordinarias	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Sector Update: Health Care Stocks Mixed Wednesday Afternoon	17/04
Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise	17/04
Celldex Therapeutics : Corporate Presentation	17/04
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	17/04
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	17/04
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	08/03
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares	06/03
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference	06/03
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference	05/03
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares	05/03
Celldex Therapeutics Prices $400.4 Million Common Stock Offering	01/03
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock	01/03
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering	28/02
Celldex Therapeutics Announces Proposed Public Offering of Common Stock	28/02
Sector Update: Health Care Stocks Weaker Monday Afternoon	26/02
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates	26/02
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria	26/02
Sector Update: Health Care Stocks Mixed Premarket Monday	26/02
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell	26/02
Celldex: Q4 Earnings Snapshot	26/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Celldex Therapeutics, Inc.

Acciones

CLDX

US15117B2025

Otros idiomas

Filtros